XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Options Issued and Outstanding Activities

Stock options issued and outstanding under the Lucid Diagnostics Inc. 2018 Equity Plan for the period indicated is as follows:

 

   Number
Stock
Options		   Weighted
Average
Exercise
Price		   Remaining
Contractual
Term
(Years)		 
Outstanding stock options at December 31, 2020   1,399,243   $0.61    8.0 
Granted(1)   —   $—      
Exercised   —   $—      
Forfeited   —   $—      
Outstanding stock options at September 30, 2021   1,399,243   $0.61    7.5 
Vested and exercisable stock options at September 30, 2021   1,120,526   $0.57    7.4 

 

(1) Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter, and have a ten-year contractual term from date-of-grant.
Schedule of Stock-Based Compensation Expense

The stock-based compensation expense recognized by the Company for both the Lucid Diagnostics Inc. 2018 Equity Plan and the PAVmed Inc. 2014 Equity Plan, for the periods indicated, was as follows:

 

   Three Months Ended
September 30,		   Nine Months Ended
September 30,		 
   2021   2020   2021   2020 
Lucid Diagnostics Inc 2018 Equity Plan – general and administrative expense  $2,694,882   $—   $5,988,299   $— 
Lucid Diagnostics Inc 2018 Equity Plan – research and development expenses   21,864    13,114    57,156    39,344 
PAVmed Inc 2014 Equity Plan - research and development expenses   56,456    3,251    111,084    9,750 
Total stock-based compensation expense –
recognized by Lucid Diagnostics Inc		  $2,772,202   $16,365   $6,156,539   $49,094 
Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period

As of September 30, 2021, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options granted under each of the Lucid Diagnostics Inc. 2018 Equity Plan and the PAVmed Inc. 2014 Equity Plan, as discussed above, is as follows:

 

   Unrecognized
Stock-Based
Compensation
Expense		   Weighted Average
Remaining
Service Period		 
Lucid Diagnostics Inc. 2018 Equity Plan          
Stock Options  $14,970    0.3 years 
Restricted Stock Awards  $17,491,130    1.5 years 
PAVmed Inc. 2014 Equity Plan          
Stock Options  $520,665    2.5 years